Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Cancer Immunology, Immunotherapy : CII|October 23, 2025
Development of antigen multimers for detection and evaluation of CAR T cellsRasmus U W Friis, Maria Ormhøj, Cecilie S Krüger-Jensen, et al.
Cell Reports. Medicine|February 10, 2024
Merkel cell polyomavirus-specific and CD39<sup>+</sup>CLA<sup>+</sup> CD8 T cells as blood-based predictive biomarkers for PD-1 blockade in Merkel cell carcinomaHeeju Ryu, Timothy M Bi, Thomas H Pulliam, et al.
Nature Biotechnology|November 20, 2018
T cell receptor fingerprinting enables in-depth characterization of the interactions governing recognition of peptide-MHC complexesAmalie K Bentzen, Lina Such, Kamilla K Jensen, et al.
Cancer Immunology Research|June 17, 2024
Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint PathwaysSigne K Skadborg, Simone Maarup, Arianna Draghi, et al.
Journal for Immunotherapy of Cancer|December 9, 2024
DNA barcoded peptide-MHC multimers to measure and monitor minor histocompatibility antigen-specific T cells after allogeneic stem cell transplantationKyra J Fuchs, Marcus Göransson, Michel G D Kester, et al.
European Journal of Immunology|January 3, 2013
Conditional ligands for Asian HLA variants facilitate the definition of CD8+ T-cell responses in acute and chronic viral diseasesCynthia X L Chang, Anthony T Tan, Ming Yan Or, et al.
Nature|June 29, 2016
Neoantigen landscape dynamics during human melanoma-T cell interactionsEls M E Verdegaal, Noel F C C de Miranda, Marten Visser, et al.
The Journal of Clinical Investigation|April 2, 2013
Discovering naturally processed antigenic determinants that confer protective T cell immunityPavlo Gilchuk, Charles T Spencer, Stephanie B Conant, et al.
Biorxiv : the Preprint Server for Biology|September 25, 2023
Interferon-α promotes neo-antigen formation and preferential HLA-B-restricted antigen presentation in pancreatic β-cellsAlexia Carré, Zhicheng Zhou, Javier Perez-Hernandez, et al.
BMC Cancer|June 17, 2020
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trialRelinde I Y Lieverse, Evert J Van Limbergen, Cary J G Oberije, et al.
Pageof 3